Introduction: Avacopan, a selective C5a receptor inhibitor, has emerged as a potential corticosteroid-sparing treatment in ANCA-associated vasculitis (AAV). This study aims to evaluate its real-world efficacy and safety in Portuguese patients with active AAV. Methods: We conducted a multicenter retrospective analysis of 15 adult patients with newly diagnosed or relapsing AAV treated with avacopan across nine ac...